Recommended for general use within NHS Scotland.
Dutasteride has demonstrated similar efficacy and safety to alternative 5a-reductase inhibitors in reducing prostate volume in patients with BPH.
Dutasteride is likely to be costneutral to NHS Scotland in the treatment of BPH.
Download detailed advice22KB (PDF)
- Medicine name:
- Dutasteride (Avodart®)
- SMC ID:
- Moderate to severe symptoms of benign prostatic hyperplasia
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Date advice published
- 09 May 2003